NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company’s flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.
Happy International Clinical Trials Day! Thank you to the Patients, Physicians, Investigators, and Health Care Professionals who make the advancement of medicine possible through their dedication and participation in Clinical Trials.
#InternationalClinicaTrialsDay#CTD2024
Headed to Toronto this weekend?
Come and listen to Dr. Ryuta Seguchi from New Heart Watanabe Institute talk about NeoChord and his experience brining this technology to patients in Japan.
Saturday 5:15pm Rm 715 “ Outcomes and Features of Transventricular Off-pump Mitral Valve Neochord Implantation for Asian Patients”
American Association for Thoracic Surgery (AATS)Ryuta Seguchi
The Dot team are delighted to be representing PulseCath BV, NeoChord, Inc. and #CircaScientific at the London Core Review Meeting in London this week! Great lectures as always. Thank you for having us Aziz Momin
We are excited to share this video with you all, highlighting a real patients experience after their mitral valve was repaired using NeoChord, Inc.
Mr Alan Fawn underwent the NeoChord procedure at Brighton Hospital in December 2023, carried out by Mr Ahmed Ishtiaq
His quality of life was improved so dramatically that he wanted to share his experience with others who may also be a suitable candidate for the NeoChord procedure.
For any questions, please contact info@dot-medical.com or call 01625 668811.
Thanks for watching!
#MitralSurgery#MitralValve#PatientStory
Today is one of those days when I realize how cool and special my job is and how great it is to work at the Maastricht UMC+. Today, along with the other members of the valve team, I helped an older patient (80+) because of a combined significant aortic valve stenosis and significant primary mitral valve insufficiency (prolapse with partial flail P2/3). It was an independent elder who, until recently, was still pruning the hedge and fully caring for the garden but suddenly became severely dyspneic (NYHA 3). The patient was not keen on a classic surgical AVR and MVP with sternotomy, considering the age and peripheral vasculature with increased risk. After extensive discussion by the valve team and weighing the different options (TF-TAVI with M-TEER, TA-TAVI with TA-Neochords, or TA-TAVI with TA-TMVR), we chose what we believed to be the best option based on anatomy and patient characteristics: TA-TAVI and TA-Neochord…thus, an AVR and MVP through the same transapical approach on a beating heart. So, no heart-lung machine, no sternotomy, just a small lateral thoracotomy, and transapical access. M-TEER was considered, but she had a relatively small valve and already a mean gradient of 5 mmHg (during significant MR!). TA-Neochords does not reduce the ostium, hence our preference in this case. In 1 hour and 15 minutes, the significant AS was relieved by a well-functioning TAVI prosthesis, and the significant MI was reduced to a trace MI (by deliberate overcorrection of the prolapse). Can you imagine a classic surgical AVR and MVP within 1.5 hours? No! This, I believe, is a significant advantage for the older patient, no long operation, no major surgical trauma, and no heart-lung machine. These treatments are possible because, as a valve team at MUMC+, we have a large arsenal of treatment options available for the mitral, tricuspid, and aortic valves. More importantly, we work very closely as a cardiac surgery and cardiology team, and no patient undergoes treatment without the specialized and dedicated valve team making the decision. This dedication and cooperation are, in my opinion, extremely important and the very best for the patient.
Thanks to the other valve team members Peyman Sardari Nia, Suzanne Kats, MD, PhD, MBA, Leo Veenstra, Jindra Vainer, Ralph Theunissen, Pieter Vriesendorp, Ralph Dudink and Patrique Segers.
#mitralvalve#aorticvalve#mitralregurgitation#aorticstenosis#combinedvalvedisease#TAVI#TAVR#Neochords#Neochord#DS1000#transapical#combotherapy#MTEER#mitraclip#pascal#carillon#transcathetervalveinterventions#transcatheter#dedication#dedicatedvalveteam#valveteam#valvularheartdisease#VHD#MUMC#MaastrichtUMC#cardiacsurgery#interventionalcardiology#imagingcardiology#mitralisklep#hartklep#kleplijden#mitralisklepinsufficientie#aortaklep#aortaklepstenose#THI
Congratulations to the team of Dr. Corey Adams and Dr. William Kent from the Department of Cardiac Surgery at the Libin Cardiovascular Institute at the Foothills Medical Centre in Calgary. They recently completed their training to be certified as a NeoChord Independent Center. Also, a special Thank You to our distribution partner RSK Medical.
These NeoChord cases were completed under the Health Canada Special Access Program.